tbuckley/cabot-search huggingface dataset:
Bulletin Johns Hopkins Hospital, Baltimore
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chronic dyspnea, ascites, and muffled heart sounds
Authors: A. Alizadeh
Journal: JAMA (1976)

<h3>History</h3> An 18-year-old woman had a history of increasing abdominal enlargement and dyspnea of five years' duration. There was mild cyanosis, distended neck veins, muffled heart sounds, abdominal dullness, and liver enlargement on physical examination. Posteroanterior and lateral chest roentgenograms were taken. <h3>Diagnosis</h3> Constrictive pericarditis with pericardial calcification. Figure 1 shows moderate cardiac enlargement and a calcified plaque along the left contour just below the pulmonary artery. Figure 2 shows a calcific ring almost completely encircling the heart. The cause of constrictive pericarditis remains in doubt in many patients.<sup>1</sup>In some cases, there is a high percentage of tuberculous origin. In other series, tuberculosis has been an infrequent cause. The disorder may also occur following pyogenic infections, connective tissue and neoplastic disease, trauma, radiation, histoplasmosis, active viral infection, asbestosis, and chronic renal failure with uremia. In nearly 50% of patients with constrictive pericarditis, pericardial calcifications can be demonstrated roentgenographically.
A phase I trial combining motexafin gadolinium with docetaxel in the treatment of advanced solid tumors
Authors: S. Phan, P. Messina, M. Buffan, M. L. Salemi, K. Pandya
Journal: Journal of Clinical Oncology (2004)

3203 Background: Motexafin gadolinium (Xcytrin) is a novel therapeutic that concentrates in tumors and generates reactive oxygen species. Pre-clinical models show that motexafin gadolinium enhances in tumors the cytotoxic activity of selected chemotherapies, including taxanes. This phase I trial treated patients with combined motexafin gadolinium and docetaxel. Methods: Patients with advanced solid tumors, adequate bone marrow, hepatic and renal function were eligible. Cohorts of 3 pts were treated with motexafin gadolinium, starting at 2.5 mg/kg followed 30 minutes later by docetaxel 75 mg/m2. Treatments were repeated q3wks. The primary objective was to determine the maximum tolerated dose (MTD) of the combination on this schedule and to determine the dose limiting toxicities (DLT). The secondary objective was to evaluate the response rate of tumors to the treatment regimen. Motexafin gadolinium dose was escalated in successive cohorts while docetaxel dose remained fixed. Results: Six pts were treated at motexafin gadolinium (2.5- 5mg/kg). There were 2 males/4 females with a median age of 68.5 yrs (range 53–76). Diagnoses included prostate (1); ovarian (2); lung (2); breast (1). Pts had had a median of 1 prior chemotherapy regimens (range 1–13), 5 pts had previously received a taxane. Reported toxicities in more than one patient include urine discoloration from excretion of motexafin gadolinium, fatigue, diarrhea and nausea, but DLT has yet to be defined. Responses are reported as follows: PR by CT in breast and by PSA in prostate, SD in lung, and PD in ovarian ca. Conclusion: Motexafin gadolinium in combination with docetaxel is feasible and did not increase docetaxel toxicity at the doses used, and may show clinical benefit as the study continues. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Pharmacyclics, Inc. Pharmacyclics, Inc. Pharmacyclics, Inc. Pharmacyclics, Inc.
Modified Instrument for Thoracentesis, Paracentesis, and Intravenous Fluid Therapy
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Endocrine Society 1981 Annual Meeting—Cincinnati, Ohio June 17–19, 1981
Journal: Endocrine Reviews (1981)

Journal Article The Endocrine Society 1981 Annual Meeting—Cincinnati, Ohio June 17–19, 1981 Get access Endocrine Reviews, Volume 2, Issue 2, 1 April 1981, Pages 248–249, https://doi.org/10.1210/edrv-2-2-248 Published: 01 April 1981
PHARMACEUTICAL NOTES
Authors: HERBERT SKINNER
Journal: British Journal of Dermatology (1898)

Journal Article PHARMACEUTICAL NOTES Get access HERBERT SKINNER HERBERT SKINNER Pharmacist to the Great Northern Central Hospital, London Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 10, Issue 10, 1 October 1898, Pages 355–358, https://doi.org/10.1111/j.1365-2133.1898.tb16300.x Published: 01 October 1898
Leads from the MMWR. Additional recommendations to reduce sexual and drug abuse-related transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOK REVIEWS
Authors: J. L. WARE
Journal: JNCI Journal of the National Cancer Institute (1989)

BOOK REVIEWS Get access Tumor Progression and Metastasis. Garth L. Nicolson, Isaiah J. Fidler, eds. New York: Alan R. Liss, Inc., 1988, 320 pp. $140. JOY L. WARE JOY L. WARE Department of PathologyP.O. Box 662 Medical College of Virginia Virginia Commonwealth University Richmond, VA 23298-0001 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 14, 19 July 1989, Page 1102, https://doi.org/10.1093/jnci/81.14.1102 Published: 19 July 1989
Deutsche Medizinische Wochenschrift, Stuttgart
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Author Name Tagging
Authors: Ronald The, Euphemia Mu, Ronald Perelman, Nicholas Soter
Journal: JAMA Dermatology (2015)

Robert Denison Griffith, MD; Brian J. Simmons, BSc; Mohammad-Ali Yazdani Abyaneh, BSc; Fleta N. Bray, BSc; Leyre A. Falto-Aizpurua, MD; Keyvan Nouri, MD
Enzalutamide monotherapy: One-year extended follow-up of a phase 2 study in hormone-naive prostate cancer patients.
Authors: Bertrand F. Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Hendrik Van Poppel, Axel Heidenreich, Peter Iversen, Johan Braeckman, Jiri Heracek, Edwina Baskin-Bey, Taoufik Ouatas, Frank Perabo, De Phung, Mohammad Hirmand, Matthew Raymond Smith
Journal: Journal of Clinical Oncology (2014)

5068 Background: The efficacy and safety of enzalutamide monotherapy was assessed in men with any-stage hormone-naive prostate cancer eligible for androgen-deprivation therapy (ADT). The primary endpoint of PSA response rate (≥80% PSA decrease between baseline and week 25) was 92.5% (Smith M et al, ASCO 2013). The median (range) maximum PSA decline from baseline to week 25 was –99.6% (–100, –86.5). 1-year extended follow-up data are presented. Methods: In an open-label, single-arm Phase 2 study (NCT01302041), men ≥18 years with histologically confirmed prostate cancer requiring ADT, non-castrate testosterone (≥8 nmol/L), PSA ≥2 ng/mL at screening, and a life expectancy of ≥12 months, received 160 mg enzalutamide once daily until disease progression or unacceptable toxicity. Other endpoints included changes in hormone levels, metabolic parameters, BMD, safety, and quality of life (QoL). Results: 67 men were enrolled. Median (range) age was 73 years (48–86); 38.8% had metastases; 35.8% and 23.9% had undergone prior prostatectomy and radiotherapy, respectively. 54 men (80.6%) completed 1 year of treatment with a PSA response rate of 100% and 53 (98.1%) had ≥90% PSA decrease from baseline. The median (range) maximum decline in PSA was –100% (–100, –86.5) from baseline to 1 year. Luteinizing hormone and testosterone were increased from baseline by 215.2% and 101.7%, respectively. Mean changes from baseline for fasting metabolic variables were: +5.0% total cholesterol, +8.9% triglycerides, –3.5% HbA1c, and +19.7% insulin resistance (HOMA-IR). Total body BMD was maintained (–0.3% from baseline). The most frequently reported treatment-emergent AEs were gynecomastia (47.8%) and fatigue (38.8%). Seven non-drug-related serious AEs were reported. Qol scores at 1 year demonstrate maintenance of global health status and a decrease in sexual activity and sexual functioning. Conclusions: Extended follow-up of hormone-naive patients demonstrated sustained PSA reductions up to 1 year of enzalutamide monotherapy. Endocrine and metabolic changes, and AEs were consistent with potent AR inhibition and similar to results reported at 25 weeks. Clinical trial information: NCT01302041.
Miscellaneous I
Authors: J. L. Bòveda T, J. C. Ruiz R, F. J. de Latorre A, M. T. Gonzalez A, R. Boye P, J. Monasterio A, B. Allaouchiche, C. Bernard, C. Nedey, F. Sabben, F. Ganichot, J. Marti-Flich, E. Combourieu, R. G. Patrigeon, F. Mignot, B. Palmier, M. A. Estecha, M. A. Romera, M. Nieto, J. M. Molina, J. J. Rubio, C. Torrecilla, A. Durocher, G. Cadelis, F. Saulnier, F. Herengt, F. Wattel, J. Asmussen, S. Gellett, H. Pilegaard, F. Gottrup, I. P. West, R. G. Griffiths, R. Holmes, S. L. Snowdon, G. R. Jones, T. H. Clutton-Brock, S. P. Hendry, S. Fink, D. J. Cook, A. N. Veligotsky, V. F. Tarasov, A. I. Sheremet, N. A. Volkova, E. Ozyilkan, O. Ozyilkan, M. E. Korkmaz, B. Kayhan, Y. Bayraktar, E. Karaagaoglu, S. Asian, H. Telatar, J. M. Rabanal, J. A. Amado, A. Quesada, F. López-Espadas, G. Regañón, X. Forns, J. M. Salmerón, A. Mas, E. Valderrama, G. Cabal, A. Rimola, J. Rodés, P. Evrard, A. Dive, M. Gonzalez, L. Delaunois, J. C. Schoevaerdts, E. Installé, L. Sollazzi, V. Perilli, A. W. Avolio, S. Agnes, G. Morelli, P. Bozza, C. Modesti, S. Bradariolo, M. Castagneto, Ch. -F. Wolf, A. Brinkmann, C. Meyerhoff, A. Grünert, F. S. Keck, B. Guidet, F. Staikowsky, T. Vassal, G. Offenstadt, P. Amstutz
Journal: Intensive Care Medicine (1992)
ABSTRACTS
Journal: Circulation (1955)

A case is presented of a patient with bacteremia due to Streptococcus viridans and Brucella abortus.It is probable that the patient had brucellosis with bacterial endocarditis due to Streptococcus veridans, although endocarditis due to both organisms cannot be ruled out.The patient recovered after therapy which included chlortetracycline (Aureomy-cin), streptom cin, and sulfadiazine and has remained well.
Large trial finds ticlopidine superior to aspirin in preventing stroke
Authors: B. Merz
Journal: JAMA (1989)

IT'S A NEW CHEMICAL entity, and no one is sure exactly how it works, but ticlopidine hydrochloride appears to work better than aspirin in staving off stroke in high-risk patients, according to the results of a 55-center trial. That was the word from William K. Hass, MD, one of the principal investigators of the Ticlopidine/Aspirin Stroke Study. Hass summarized the study's results at the recent 14th International Joint Conference on Stroke and Cerebral Circulation in San Antonio, Tex. Hass, professor of neurology at New York (NY) University School of Medicine, told the conference that the drug, developed by Syntex Corporation, Palo Alto, Calif, was superior to aspirin in preventing both fatal and nonfatal strokes. He said that the side effects were minor and reversible. The study undertaken in 1981 involved 3069 patients who had suffered a transient ischemic attack or a more prolonged, but reversible, ischemic deficit within the 90
In-Training Examination in Internal Medicine
Authors: James R. O'Dell
Journal: Annals of Internal Medicine (1995)

Letters1 January 1995In-Training Examination in Internal MedicineJames R. O'Dell, MDJames R. O'Dell, MDUniversity of Nebraska Medical Center; Omaha, NE 68198-3025Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-122-1-199501010-00033 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:As an internal medicine program director, I read with interest the recent article by Garibaldi and colleagues on the ITE-IM [1]. Since the ITE-IM was first offered in 1988, we have required that all of our first-, second-, and third-year residents take the examination each year, allowing us to follow the early progress (as measured by the examination) of all our residents.During this period we have evaluated the correlation between the performance of our residents on the ITE-IM in relation to their results on the ABIM certifying examination. We have found an even stronger correlation between ...References1. Garibaldi RA, Trontell MC, Waxman H, Holbrook JH, Kanya DT, Khoshbin S, et al. The In-Training Examination in Internal Medicine. Ann Intern Med. 1994; 121:117-23. Google Scholar2. Grossman RS, Fincher RM, Layne RD, Seelig CB, Berkowitz LR, Levine MA. Validity of the in-training examination for predicting American Board of Internal Medicine Certifying Examination scores. J Gen Intern Med. 1992; 7:63-7. Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Nebraska Medical Center; Omaha, NE 68198-3025 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byImpact of subspecialty elective exposures on outcomes on the American board of internal medicine certification examinationA Prospective Study of the Relationship between Medical Knowledge and Professionalism among Internal Medicine Residents 1 January 1995Volume 122, Issue 1Page: 73-74 Issue Published: 1 January 1995 Copyright & PermissionsCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Questions About Genetic Variation in 9p21 as a Predictor of Cardiovascular Risk
Authors: Nina P. Paynter
Journal: Annals of Internal Medicine (2009)

Letters19 May 2009Questions About Genetic Variation in 9p21 as a Predictor of Cardiovascular RiskNina P. Paynter, PhD, Nancy R. Cook, ScD, and Paul M Ridker, MD, MPHNina P. Paynter, PhDFrom Brigham and Women's Hospital, Boston, MA 02215.Search for more papers by this author, Nancy R. Cook, ScDFrom Brigham and Women's Hospital, Boston, MA 02215.Search for more papers by this author, and Paul M Ridker, MD, MPHFrom Brigham and Women's Hospital, Boston, MA 02215.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-150-10-200905190-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We appreciate the interest in our article and the opportunity to address readers' questions.Drs. Gulcher and Stefannson bring up the distribution of risk in the study population. Although it is correct that the overall risk in our population is low, other variables have improved prediction in this cohort (1). We do not believe that examining the utility of 9p21 genotype in risk classification of a higher-risk population would necessarily show different results, and we look forward to analyses done in different cohorts. Unfortunately, neither of the studies cited by Drs. Gulcher and Stefannson have examined whether the ...Reference1. Cook NR. Comments on ‘Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond’ by M. J. Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929). Stat Med. 2008;27:191-5. [PMID: 17671959] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Brigham and Women's Hospital, Boston, MA 02215.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCardiovascular Disease Risk Prediction With and Without Knowledge of Genetic Variation at Chromosome 9p21.3 Nina P. Paynter , Daniel I. Chasman , Julie E. Buring , Dov Shiffman , Nancy R. Cook , and Paul M. Ridker Questions About Genetic Variation in 9p21 as a Predictor of Cardiovascular Risk Jeff Gulcher and Kari Stefansson Questions About Genetic Variation in 9p21 as a Predictor of Cardiovascular Risk Lukasz Kiljanek Questions About Genetic Variation in 9p21 as a Predictor of Cardiovascular Risk John R. Schwarzenbach Metrics 19 May 2009Volume 150, Issue 10Page: 737KeywordsC-reactive proteinsCardiovascular diseasesConflicts of interestForecastingGeneticsMyocardial infarctionStatins ePublished: 19 May 2009 Issue Published: 19 May 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Measurement of Respiratory Morbidity in General Practice in the United Kingdom during the Acid Transport Event of January 1985
Authors: Jon Ayres, Douglas Fleming, Martin Williams, Gordon McInnes
Journal: Environmental Health Perspectives (1989)

The Weekly Returns System of the Royal College of General Practitioners was used to assess the effect on respiratory illness of the acid transport event that occurred during January 1985. The pollution event, as assessed by SO2 and smoke levels measured at pollution monitoring stations within and without the affected area showed only modest rises in SO2 levels, which were less than levels that occurred 4 years earlier. January is the peak time of year for reporting of acute respiratory episodes, and the minor increase in pollution was not reflected in any rise in respiratory morbidity, both for all ages and for different age bands. There was a rise in rates for children up to the age of 14, but this was seen each year and in both polluted and nonpolluted areas. This was probably due to children returning to school after the winter vacation and the subsequent spread of viral infections. The limitations of the two data sets in this analysis are discussed, including the relative insensitivity of weekly data in picking out a short-lived event, the distribution of the practices and pollution monitoring stations, and the effect of the extreme cold weather and the coal miners' strike on domestic coal burning during this event.
Designing Case-Control Studies
Authors: Takashi Yanagawa
Journal: Environmental Health Perspectives (1979)

Identification of confounding factors, evaluation of their influence on cause-effect associations, and the introduction of appropriate ways to account for these factors are important considerations in designing case-control studies. This paper presents designs useful for these purposes, after first providing a statistical definition of a confounding factor. Differences in the ability to identify and evaluate confounding factors and estimate disease risk between designs employing stratification (matching) and designs randomly sampling cases and controls are noted. Linear logistic models for the analysis of data from such designs are described and are shown to liberalize design requirements and to increase relative risk estimation efficiency. The methods are applied to data from a multiple factor investigation of lung cancer patients and controls.